BTIG Research reaffirmed their hold rating on shares of Illumina (NASDAQ:ILMN) in a research report report published on Tuesday morning.

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research raised Illumina from a hold rating to a buy rating and set a $229.00 target price for the company in a report on Friday, October 27th. Deutsche Bank raised Illumina from a hold rating to a buy rating and decreased their price target for the company from $195.00 to $160.00 in a research note on Monday, October 23rd. Canaccord Genuity reissued a buy rating and issued a $230.00 price target (up previously from $215.00) on shares of Illumina in a research note on Thursday, October 12th. Vetr raised Illumina from a hold rating to a buy rating and set a $217.50 price target for the company in a research note on Tuesday, September 19th. Finally, Bank of America increased their price target on Illumina from $215.00 to $240.00 and gave the company a buy rating in a research note on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $220.13.

Shares of Illumina (ILMN) traded up $2.24 on Tuesday, reaching $243.55. The company’s stock had a trading volume of 894,757 shares, compared to its average volume of 1,098,233. Illumina has a fifty-two week low of $156.50 and a fifty-two week high of $248.97. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The firm has a market cap of $35,560.00, a PE ratio of 45.95, a PEG ratio of 3.25 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same quarter in the prior year, the firm earned $0.97 EPS. The business’s revenue for the quarter was up 17.6% compared to the same quarter last year. equities analysts forecast that Illumina will post 3.76 earnings per share for the current fiscal year.

In related news, Director Jay T. Flatley sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $243.72, for a total transaction of $3,655,800.00. Following the completion of the sale, the director now owns 449,201 shares of the company’s stock, valued at $109,479,267.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Marc Stapley sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $205.48, for a total value of $410,960.00. Following the sale, the executive vice president now directly owns 30,370 shares of the company’s stock, valued at approximately $6,240,427.60. The disclosure for this sale can be found here. Insiders have sold 154,671 shares of company stock valued at $33,626,228 in the last ninety days. 0.89% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the business. Dupont Capital Management Corp bought a new position in Illumina in the third quarter worth approximately $153,000. Advisory Services Network LLC boosted its holdings in Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after acquiring an additional 89 shares in the last quarter. West Coast Financial LLC bought a new position in Illumina in the third quarter worth approximately $216,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in Illumina in the second quarter worth approximately $226,000. Finally, Colony Group LLC bought a new position in Illumina in the second quarter worth approximately $239,000. Institutional investors and hedge funds own 91.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Illumina (ILMN) Rating Reiterated by BTIG Research” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://theolympiareport.com/2018/01/19/illumina-ilmn-rating-reiterated-by-btig-research.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.